Introduction:
Familial Mediterranean Fever (FMF), a hereditary autoinflammatory disorder often presents with dramatic recurrent fevers and inflammation. However, a recent case study reveals a milder manifestation linked to a specific genetic polymorphismc.1588-69G>Ain the MEFV gene. This intriguing case highlights not only the variability of FMF presentations but also the importance of genetic screening in accurate diagnosis and personalized care.
Visit https://www.allergyimmunoljournal.com/ for more groundbreaking research in this field.
Genetic Clues in a Subtle Clinical Presentatio
A 54-year-old Italian woman presented with intermittent fevers, erysipelas-like rash, and joint pain symptoms aligned with FMF based on the TelHashomer criteria. Genetic analysis revealed the presence of a c.1588-69G>A polymorphism in intron 5 of the MEFV gene, a variant less commonly associated with severe forms of the disease.
Key Observations:
- Clinical Symptoms:
- Fever episodes lasting 24–72 hours
- Skin rash and arthritic attacks
- Elevated inflammatory markers: ESR, CRP, fibrinogen
- Laboratory & Imaging Findings:
- Increased leukocyte count
- Slight liver steatosis on ultrasound
- No evidence of systemic amyloidosis
- Genetic Insight:
- Single polymorphism detected in MEFV gene
- No associated mutations in TNFRSF1A or NLRP3 genes
The Role of Polymorphisms in Disease Expression
In this case and across a broader study population, the c.1588-69G>A polymorphism was found in both FMF patients and healthy individuals. However, the polymorphism appeared more frequently in FMF patients, suggesting a potential role in triggering mild forms of the disease. Notably:
- Among 167 FMF patients:
- 98 tested positive for the polymorphism
- Of those, 72 were heterozygous and 26 homozygous
- Many had no other MEFV mutations, indicating possible pathogenicity of this variant alone
- Among healthy donors:
- 21 tested positive, but rarely displayed symptoms
This evidence supports the growing need for nuanced genetic diagnostics, particularly when traditional markers or mutations are absent.
Broader Implications in Medical Genetics
The American College of Medical Genetics and Genomics (ACMG) underscores the significance of variant classification, especially for conditions with variable expressivity like FMF. This case aligns with ACMG’s guidance by highlighting how even intronic variants, often dismissed as benign, can manifest clinically under specific genetic or environmental contexts.
Additionally, similar findings have been reported among Iranian and Lebanese populations, suggesting shared regional genetic markers across the Mediterranean basin.
Treatment Challenges and Outcomes
Initial symptom resolution was achieved using corticosteroids (2 mg betamethasone). Colchicine, the standard FMF therapy, was effective but poorly tolerated due to gastrointestinal side effects. The patient is now managed symptomatically with steroids during rare flare-ups.
Read the full study at https://doi.org/10.29328/journal.aaai.1001019
Explore Related Topics
- Understanding Genetic Markers in Autoimmune Disorders
- Role of Colchicine in FMF Management
- Clinical Profiles of Mild Auto-inflammatory Diseases
Conclusion and Future Directions
This case illustrates the clinical relevance of the c.1588-69G>A polymorphism in FMF patients without classical gene mutations. As genetic testing evolves, healthcare providers must remain vigilant about such atypical presentations to ensure early diagnosis and appropriate intervention.
Explore more studies at https://www.allergyimmunoljournal.com/ and join the conversation by sharing your thoughts in the comments below
Disclaimer: This content is generated using AI assistance and should be reviewed for accuracy and compliance before considering this article and its contents as a reference. Any mishaps or grievances raised due to the reusing of this material will not be handled by the author of this article.
Heighten Science Publications Inc. 
Leave a comment